

AUSTRALIAN PRODUCT INFORMATION – LERCANIDIPINE APOTEX (LERCANIDIPINE HYDROCHLORIDE)

1 NAME OF THE MEDICINE

Lercanidipine hydrochloride

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 10 mg or 20 mg lercanidipine hydrochloride

Ingredients with known effects: lactose

For the full list of excipients, see Section 6.1 List of Excipients.

3 PHARMACEUTICAL FORM

10 mg: round biconvex yellow film coated tablets, scored on one side, marked “L” on the other side (AUST R 172204).

20 mg: round biconvex pink film coated tablets, scored on one side, marked “L” on the other side (AUST R 172206).

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Treatment of hypertension.

4.2 DOSE AND METHOD OF ADMINISTRATION

The recommended dose is 10 mg once daily, at least 15 minutes before a meal. The dose may be increased to 20 mg once daily depending on the individual response. Dose titration should be gradual, as it may take about two weeks for the maximal antihypertensive effect to be apparent. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently. Since it is unlikely that increasing the dose beyond 20 mg will further improve the efficacy, and may be associated with side effects, doses above 20 mg are not recommended. Some individuals not adequately controlled on a single antihypertensive agent may benefit from the addition of lercanidipine at the same doses used in monotherapy to the existing regimen with a beta-blocker, a diuretic or an ACE inhibitor.

Use in the elderly, children, hepatic and renal impairment

See Section 4.4 Special Warnings and Precautions for Use.

4.3 CONTRAINDICATIONS

Hypersensitivity to any dihydropyridine or any ingredient in this medicine; severe hepatic impairment; severe renal impairment (creatinine clearance < 12 mL/minute).

Concomitant treatment with cyclosporin should be avoided.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Ischaemic heart disease

It has been suggested that some short acting dihydropyridines may be associated with increased cardiovascular risk in patients with ischaemic heart disease. Although lercanidipine is long acting, caution should be required in such patients.

Outflow obstruction (aortic stenosis)

Lercanidipine should be administered with caution in patients with left ventricular outflow obstruction (aortic stenosis).

Congestive heart failure

In general, calcium channel blockers should be used with caution in patients with heart failure. Although animal data and acute haemodynamic evaluation in patients with preserved left ventricular function have not demonstrated that lercanidipine exerts a direct negative inotropic effect, safety in patients with congestive heart failure has not been established. Therefore, as for other calcium channel blockers, lercanidipine should be used with caution in such patients, especially if untreated.

Unstable angina pectoris or within one month of a myocardial infarction

Rarely patients have developed documented increased frequency, duration and/or severity of angina on starting calcium channel blocker therapy or at the time of dosage increase (particularly those with severe obstructive coronary artery disease). The mechanism of this effect has not been elucidated, however the possibility of an exacerbation of angina and/or cardiac ischaemia exists. It is, therefore, suggested that the use of calcium channel blockers is not advisable in patients with unstable angina pectoris or recent myocardial infarction.

Impaired renal function

Although the pharmacokinetics of lercanidipine in patients with mild to moderate renal impairment are similar to those observed in the general population, special care should be exercised when commencing treatment in such patients. The usual recommended dose of 10 mg daily may be tolerated; however, an increase to 20 mg daily should be approached with caution.

Peritoneal dialysis

Lercanidipine has been associated with the development of cloudy peritoneal effluent in patients on peritoneal dialysis. The turbidity is due to an increased triglyceride concentration in the peritoneal effluent. Whilst the mechanism is unknown, the turbidity tends to resolve soon after withdrawal of lercanidipine. This is an important association to recognise as cloudy peritoneal effluent can be mistaken for infective peritonitis with consequential unnecessary hospitalisation and empiric antibiotic administration.

Use in hepatic impairment

The pharmacokinetics of lercanidipine in patients with mild hepatic impairment are similar to those observed in the general population. However, there are no studies in patients with moderate hepatic impairment and dosage recommendations have not been established. Lercanidipine should, therefore, be used with caution in this patient group and careful monitoring undertaken during treatment, since the bioavailability and hypotensive effect may be increased. The use of lercanidipine in patients with moderate hepatic impairment should only be undertaken if the benefits are considered to outweigh the risks. Lercanidipine is contraindicated in patients with severe hepatic disease.

Use in the elderly

Although the pharmacokinetic data and clinical experience suggest that no adjustment of the daily dose is required, special care should be exercised when initiating treatment in the elderly.

Paediatric use

Due to lack of clinical experience, lercanidipine is not recommended for use in patients under the age of 18.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Lercanidipine has been safely administered with diuretics and angiotensin converting enzyme (ACE) inhibitors. It may also be administered safely with beta-blockers which are eliminated unchanged (such as atenolol).

Inhibitors or inducers of cytochrome CYP3A4

Since the main metabolic pathway of lercanidipine involves the enzyme CYP3A4, drugs that inhibit or induce this enzyme have the potential to alter the plasma concentration of the compound.

Therefore, inhibitors of CYP3A4 (such as ketoconazole, itraconazole, erythromycin, ritonavir and fluoxetine) may increase the plasma concentration of lercanidipine, and such combinations should be used with caution.

When coadministered with CYP3A4 inducers, such as anticonvulsants (e.g. phenytoin, carbamazepine) and rifampicin, the antihypertensive effect of lercanidipine may be reduced and, therefore, blood pressure should be monitored when the coadministration is foreseen.

CYP3A4 and CYP2D6 substrates

The potential for in vivo inhibition of CYP3A4 by lercanidipine is negligible, as confirmed by an interaction study with midazolam in healthy volunteers. After repeated coadministration with lercanidipine, midazolam (a probe for CYP3A4 activity) was found to be essentially bioequivalent to the drug administered alone. However, unless specific data are available, caution should also be exercised when lercanidipine is coprescribed with other substrates of CYP3A4 which have a narrow therapeutic index, such as cyclosporin, and class III antiarrhythmic drugs (e.g. amiodarone and quinidine).

Coadministration of lercanidipine with cyclosporin resulted in a threefold increase in the plasma levels of lercanidipine and a 21% increase in the bioavailability of cyclosporin. However, when cyclosporin was administered three hours after lercanidipine, no increase in plasma levels was observed for lercanidipine, while the bioavailability of cyclosporin increased by 27%. Therefore, cyclosporin and lercanidipine should not be administered together.

Moreover, interaction studies in humans have shown that lercanidipine did not modify the plasma levels of metoprolol, (a typical substrate of CYP2D6). Therefore, at therapeutic doses it is unlikely that lercanidipine will inhibit the biotransformation of drugs metabolised by CYP2D6.

These findings confirm that the inhibition of cytochrome P450 isoenzymes observed in vitro with lercanidipine is devoid of any clinical significance. In vitro experiments with human liver

microsomes demonstrated that lercanidipine inhibits CYP3A4 and CYP2D6 (IC₅₀ of 2.6 and 0.8 microgram, respectively). The IC₅₀ concentrations for CYP3A4 and CYP2D6 are 160 and 40 times higher, respectively, than those reached at peak in the plasma after a 20 mg dose.

Beta-blockers

When lercanidipine was administered with metoprolol, a beta-blocker eliminated mainly by the liver, the bioavailability of metoprolol was not changed, while that of lercanidipine was reduced by 50%. Therefore, when coadministered with metoprolol, it may be necessary to increase the dose of lercanidipine. It is anticipated that a similar effect may occur with propranolol.

Cardiac glycosides

Coadministration of lercanidipine in patients chronically treated with beta-methyl digoxin (a prodrug of digoxin) showed no evidence of a pharmacokinetic interaction. However, patients on concomitant digoxin treatment should be closely monitored.

Cimetidine

Concomitant administration of cimetidine 400 mg twice daily does not cause significant changes in the plasma levels of lercanidipine: AUC and C_{max} were increased by a mean of 11%. However, at higher doses caution is required since the bioavailability and the hypotensive effect of lercanidipine may be increased.

Simvastatin

Coadministration of a dose of lercanidipine 20 mg with simvastatin 40 mg resulted in no increase in the bioavailability of lercanidipine, however a 56% increase was observed for simvastatin and a 28% increase for its active metabolite beta-hydroxyacid. It is unlikely that these changes are clinically relevant. However, it is recommended that when required lercanidipine be administered in the morning and simvastatin in the evening.

Food

See Section 5.2 Pharmacokinetic Properties, Absorption.

The metabolism of dihydropyridines can be inhibited by grapefruit juice, leading to increased plasma concentration and hypotensive effect.

Alcohol should be avoided while taking lercanidipine since it may potentiate the effect of vasodilating antihypertensive drugs.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

Administration of lercanidipine at oral doses up to 12 mg/kg/day (associated with plasma lercanidipine concentration (AUC) about 20 to 40 times higher than the expected human AUC) had no effect on male or female fertility in rats.

Use in pregnancy

Category C

There is no clinical experience with lercanidipine in pregnancy, but other dihydropyridine compounds have been found to cause irreversible malformations in animals. Therefore, lercanidipine should not be administered during pregnancy or to women with childbearing potential unless effective contraception is used.

In animal studies, pregnant rats given lercanidipine orally at doses greater than or equal to 2.5 mg/kg/day beginning prior to mating, or 12 mg/kg/day beginning from early gestation, showed signs of dystocia and had an increased incidence of stillbirths and a lower neonatal survival index. The no-effect dose for effects on parturition and neonatal survival was 0.5 mg/kg/day (associated with lercanidipine concentration (AUC) about 50% of the expected human AUC) when dosing started before pregnancy or 2.5 mg/kg/day (about three times the human AUC) when dosing started during early gestation. Administration with lercanidipine at doses of 2.5 mg/kg/day during gestation also caused a higher incidence of fetal visceral abnormalities (mono/ bilateral renal pelvic and/or ureteric dilatation) and skeletal abnormalities (mainly delayed ossification) at all dose levels. A no-effect dose was not established. The effects of lercanidipine during pregnancy have not been investigated adequately in a nonrodent species.

Use in lactation

There is no clinical experience with lercanidipine in lactation. Distribution into milk may be expected, due to the high lipophilicity of lercanidipine. Therefore, lercanidipine should not be administered to lactating women.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Treatment with lercanidipine is generally well tolerated. In nine placebo controlled clinical trials with a treatment duration lasting at least four weeks, 582 patients were initially treated with lercanidipine, and 292 patients received placebo. Most of the events reported in the studies were related to the vasodilatory effects of lercanidipine, and were classified mild to moderate in severity.

Table 1 lists, according to organ system, adverse events that were reported in placebo controlled trials in hypertensive patients with lercanidipine tablets at an incidence greater than or equal to 1% in at least one of the active treatment groups.

Lercanidipine

Table 1

Adverse events in placebo controlled trials in hypertensive patients at an incidence of $\geq 1\%$ in at least one of the active treatment groups

Adverse event	Lercanidipine 10 mg once daily (%)	Lercanidipine 20 mg once daily (%)	Placebo (%)
Cardiovascular			
Flushing	2.6	2.2	1.6
Palpitations/tachycardia	1.5	1.1	0.3
Body as a whole			
Peripheral oedema	1.0	1.1	0.9
Central, peripheral nervous system			
Dizziness	1.0	0.0	0.6
Headache	4.4	4.3	2.5
Liver disorders			
GGT increased	0.0	1.1	0.3

More extensively, over 15,500 patients were treated with lercanidipine in clinical trials (including PMS studies) with doses from 2.5 mg daily up to 40 mg daily, and with treatment duration ranging from a single dose up to more than one year. Adverse experiences which were not clearly drug related and which occurred in < 1% but greater than or equal to 0.1% of patients are summarised according to organ system.

Cardiovascular. Palpitations/ tachycardia.

Central and peripheral nervous system. Dizziness, vertigo.

Gastrointestinal. Nausea, dyspepsia, abdominal pain, diarrhoea.

Psychiatric. Somnolence.

General. Flushing, asthenia (including fatigue and muscle weakness).

The following events have been rarely reported.

Cardiovascular. Hypotension, orthostatic hypotension, periorbital oedema, anginal pain, myocardial infarction, cardiac failure.

Respiratory. Dyspnoea.

Central and peripheral nervous system. Migraine, paraesthesia, leg cramps.

Special senses. Taste alteration.

Gastrointestinal. Vomiting, gastrointestinal disorder not otherwise specified (NOS).

Liver and biliary system. Gamma glutaryl transferase (GGT) increased.

Genitourinary. Polyuria, urinary frequency, impotence.

Musculoskeletal. Myalgia.

Skin and appendages. Rash, pruritus, allergic dermatitis, hives, sweating increased.

Psychiatric. Anxiety, insomnia.

Metabolic. Hypercholesterolaemia.

General. Chest pain, malaise.

Serious adverse events have been reported in clinical trials in less than 0.002% of the patients. The remaining adverse events have been reported as mild to moderate in intensity.

Laboratory tests

There were reports of isolated and reversible increases in serum levels of hepatic transaminases; no other clinically significant pattern of laboratory test abnormalities related to lercanidipine has been observed. Lercanidipine does not affect blood sugar or lipid levels.

Other adverse effects

Gastrointestinal: Cloudy peritoneal effluent (in patients on peritoneal dialysis).

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>.

4.9 OVERDOSE

Symptoms

There is limited experience with lercanidipine overdosage. As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation with marked hypotension and reflex tachycardia.

Treatment

In case of severe hypotension, bradycardia and unconsciousness, cardiovascular and respiratory monitoring will be required and supportive treatment may be necessary. Since lercanidipine is highly lipophilic, dialysis is unlikely to be effective.

For information on the management of overdose, contact the Poison Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Lercanidipine is a calcium antagonist of the dihydropyridine group and selectively inhibits the transmembrane influx of calcium into cardiac and vascular smooth muscle, with a greater effect on vascular smooth muscle than on cardiac smooth muscle. The antihypertensive action is due to a direct relaxant effect on vascular smooth muscle which lowers total peripheral resistance and hence blood pressure. Lercanidipine has a prolonged antihypertensive activity because of its high membrane partition coefficient. It is devoid of negative inotropic effects and its vascular selectivity is due to its voltage dependent calcium antagonist activity. Since the vasodilatation induced by lercanidipine hydrochloride is gradual in onset, acute hypotension with reflex tachycardia has rarely been observed in hypertensive patients.

As for other asymmetric 1,4-dihydropyridines, the antihypertensive activity of lercanidipine is mainly due to the (S)-enantiomer.

No significant effects on electrocardiogram (ECG) have been seen.

Clinical trials

Placebo controlled trials

Lercanidipine has been compared to placebo in four 4 to 16 week studies, involving 671 patients with mild to moderate essential hypertension. All studies used a three week placebo run-in period. Endpoints were diastolic and systolic blood pressure 24 hours postdose. Both 10 and 20 mg once daily significantly lowered diastolic and systolic blood pressure compared to placebo, and the reduction in blood pressure was maintained throughout the 24 hour dosing period.

Diastolic blood pressure changes observed after four weeks of treatment with lercanidipine 10 to 20 mg daily ranged between 8 and 13 mmHg, as compared to 3 to 6 mmHg induced by placebo.

Studies with 24 hour ambulatory blood pressure monitoring have documented that the antihypertensive effect of lercanidipine is maintained throughout the 24 hour dosing period, with limited variations between peak (5 to 7 hours postdosing) and trough blood pressure changes.

Active controlled studies

Four clinical trials involving 538 patients with mild to moderate essential hypertension have compared lercanidipine with nifedipine SR, atenolol, hydrochlorothiazide and captopril. Trials included a two week washout period followed by a three week placebo run-in, and 12 to 16 weeks of active treatment. Diastolic and systolic blood pressure was measured 24 hours postdose. Lercanidipine was as effective as the comparator drugs, and at least as well tolerated. 24 hour blood pressure monitoring was used in a comparative, crossover trial of lercanidipine versus amlodipine (n = 16). The effect of lercanidipine paralleled that of amlodipine throughout the 24 hour period.

Patients with isolated systolic hypertension

The effect of lercanidipine 10 to 20 mg daily on isolated systolic hypertension was studied in a double blind, randomised, placebo controlled study in 83 elderly patients (sitting systolic blood pressure > 160 mmHg and sitting diastolic blood pressure < 95 mmHg). The study consisted of one week washout, three weeks placebo run-in, and eight weeks of active treatment. Systolic and diastolic blood pressure was measured 24 hours postdose. Lercanidipine 10 to 20 mg was efficacious in lowering systolic blood pressure from the initial values of 172.6 +/- 5.6 mmHg to 140.2 +/- 8.7 mmHg (mean +/- SD, per protocol population in all patients completing the whole eight weeks of double blind treatment), as compared to the changes in the placebo group (from 172.4 +/- 6.3 to 162.8 +/- 9.7 mmHg). Therefore, at study endpoint, patients treated with lercanidipine experienced a significantly greater decrease (-22.6 mmHg, p < 0.001) in sitting systolic blood pressure in comparison to placebo. The diastolic blood pressure was within normal range.

Long-term studies

In long-term studies, 399 patients were followed for 12 months, with dose titration allowed every four weeks, to 30 mg daily. Development of tolerance was not seen. The antihypertensive effect was maintained and the heart rate was not significantly affected. A further fall in blood pressure was seen after the first and second month, with blood pressure stabilising in the third month. The majority of patients remained on 10 mg once daily.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Lercanidipine is completely absorbed after oral administration. Peak plasma levels of 3.30 nanogram/mL +/- 2.09 SD and 7.66 nanogram/mL +/- 5.90 SD occur 1.5 to 3 hours after dosing with 10 and 20 mg, respectively. The absolute bioavailability of lercanidipine is about 10%, because of high first-pass metabolism. The bioavailability increases fourfold when lercanidipine is ingested up to two hours after a high fat meal, and about twofold when taken immediately after a carbohydrate rich meal. Consequently, lercanidipine should be taken at least 15 minutes before a meal.

With oral administration, lercanidipine exhibits nonlinear kinetics. After 10, 20 or 40 mg, peak plasma concentrations observed were in the ratio 1:3:8 and areas under plasma concentration-time curves (AUC) in the ratio 1:4:18, showing a progressive saturation of first-pass metabolism. Accordingly, bioavailability increases as dosage increases.

The two enantiomers of lercanidipine have a similar time to peak plasma concentration. The peak plasma concentration and AUC are, on average, 1.2-fold higher for the (S)-enantiomer. No in vivo interconversion of enantiomers is observed.

Distribution

Distribution of lercanidipine from plasma to tissues and organs is rapid and extensive. Serum protein binding exceeds 98%. The free fraction of lercanidipine may be increased in patients with renal or hepatic impairment as plasma protein levels are decreased in these disease states.

Metabolism

As for other dihydropyridine derivatives, lercanidipine is extensively metabolised by CYP3A4. It is predominantly converted to inactive metabolites; no parent drug is found in the urine or faeces. About 50% of the dose is excreted in the urine.

Excretion

The mean terminal elimination half-life of S- and R-lercanidipine enantiomers is 5.8 +/- 2.5 and 7.7 +/- 3.8 hours, respectively. No accumulation was seen upon repeated administration. The therapeutic activity of lercanidipine lasts for 24 hours, due to its high binding to lipid membranes.

Elderly patients

In elderly patients, the pharmacokinetics of lercanidipine are similar to those observed in the general population.

Hepatic impairment

A study in patients with mild hepatic impairment (Child-Pugh class A) showed that the pharmacokinetic behaviour of the drug is similar to that observed in the general population. No studies have been undertaken in patients with moderate or severe hepatic impairment.

Renal impairment

In patients with severe renal dysfunction (creatinine clearance < 12 mL/minute) or dialysis dependent patients, plasma levels were increased by about 70%. As a consequence, the drug should be contraindicated in severe renal impairment.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

No evidence for genotoxic activity was observed with lercanidipine in in vitro assays of gene mutation (reverse mutation in *S. typhimurium*, forward mutation in Chinese Hamster V79 fibroblasts), gene conversion (in *Saccharomyces cerevisiae* D4) or chromosomal damage (Chinese hamster ovary (CHO) cytogenetic assay). Negative findings were also obtained with lercanidipine in an in vivo assay of chromosomal damage (mouse micronucleus test).

Carcinogenicity

Carcinogenicity studies of lercanidipine (administered via the diet) have been performed in rats and mice (18 months), using doses up to 60 mg/kg/day for mice and 5 mg/kg/day for rats. Plasma concentrations (AUC) of lercanidipine at the highest doses used in these studies were about two to four times the highest AUC expected in humans during treatment with lercanidipine. Lercanidipine showed no evidence of carcinogenic activity in these studies.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Lactose, microcrystalline cellulose, sodium starch glycollate, povidone, magnesium stearate and the film coating ingredient Opadry II Yellow 85F32553 [which contains polyvinyl alcohol, titanium dioxide, macrogol 3350, purified talc and iron oxide yellow (10 mg tablets)] or Opadry II Pink 85F34564 [which contains polyvinyl alcohol, titanium dioxide, macrogol 3350, purified talc and iron oxide red (20 mg tablets)].

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C. Protect from light.

6.5 NATURE AND CONTENTS OF CONTAINER

10 mg: Blister (PVC/PVDC/Al) pack of 28 tablets


20 mg: Blister (PVC/PVDC/Al) pack of 28 tablets

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure



Chemical name: 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride.

Molecular formula: $C_{36}H_{41}N_3O_6 \cdot HCl$

MW: 648.2 (free base 611.7)

Lercanidipine hydrochloride is a microcrystalline, odourless, citrine powder, readily soluble in chloroform and methanol, practically insoluble in water. Octanol: water partition coefficient (LogP): 6.4.

Lercanidipine is a dihydropyridine derivative. It is a racemate due to the presence of a chiral carbon atom at position 4 of the 1,4-dihydropyridine ring.

CAS number

132866-11-6

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8 SPONSOR

Medis Pharma Pty Ltd
1002/53 Walker St
North Sydney NSW 2060

Tel: (02) 9251 1088
www.medis.is/location/Australia/

Distributor

Apotex Pty Ltd
16 Giffnock Avenue
Macquarie Park NSW 2113

Tel: (02) 8877 8333
www1.apotex.com/au

9 DATE OF FIRST APPROVAL

30 June 2011

10 DATE OF REVISION

10 October 2018

Summary table of changes

Section(s) changed	Summary of new information
n.a.	Reformatted Product Information
Title & 4.3 3 6.1 6.5 8	Trade Name changes Correction of dosage form and inclusion of AUST R numbers Use of AANs Pack type, material and size included Sponsor & Distributor contact details inserted